Biotech News

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PolyPid (PYPD)PolyPid2026-06-25 13:46 ESTFDA / regulatory

NDA to be Submitted on a Rolling Basis, Beginning Early 2026 PETACH TIKVA, Israel , Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New

Open original release

Related news

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PYPDPolyPid2026-06-25 13:46 EST

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PYPDPolyPid2026-06-25 13:46 EST

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Announces Participation in Upcoming Investor Conferences

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PYPDPolyPid2026-06-25 13:46 EST

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

View all latest news

PolyPid

PolyPid is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

PYPDPolyPid2026-06-26 07:17 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PYPDPolyPid2026-06-26 07:17 EST

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PYPDPolyPid2026-06-26 07:17 EST

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PYPDPolyPid2026-06-26 07:17 EST

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PYPDPolyPid2026-06-26 07:17 EST

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States